Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo

Detalhes bibliográficos
Autor(a) principal: Moreira, Wagner Brant
Data de Publicação: 2023
Outros Autores: Brandão, Eduardo Carvalho, Nascimento, Eduardo, Lopes, Eugênio Baumgratz, Teixeira, João Augusto M., Vieira, Maria do Carmo L. R., Alvares, Maria Nunes, Cabral Filho, Sebastião
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3238
Resumo: Twenty eight available patients with advanced germ cell testis cancer were treated by combination chemotherapy (CT) with Cisplatinun, Vinblastine and Bleomycin (PVB) and followed by a median period of 35.5 months (range 5-76). Complete remission (CR) with CT alone was achieved in 12/28 (431%) patients, CR with CT associated to radical surgery in 4/28 (14%) patients, with a total of 16/28 (57%) patients becoming disease-free. CR was achieved in 6/7 (86%) patients with minimal advanced disease and alI of them are long term disease free survivors. CR was achieved in 10/21 (47,6%) patients with bulky advanced disease and five (24%) of them are still in their first remission. PVB was an effective and well tolerated treatment for patients with minimal advanced disease but were of less eficacy (only 24% Jong term disease free survivors) in those with bulky disease. Survival curve as described by Kaplan-Meier method, showed a media, survival of 36.6 months and a four-year disease free survival of 48010 patients. Discussion about new chemotherapeutic treatments are presented.
id INCA-1_10b16a584c2e306c55eaf4830473757c
oai_identifier_str oai:rbc.inca.gov.br:article/3238
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do TesticuloTumor TesticularQuimioterapiaTesticular TumorChemotherapyTwenty eight available patients with advanced germ cell testis cancer were treated by combination chemotherapy (CT) with Cisplatinun, Vinblastine and Bleomycin (PVB) and followed by a median period of 35.5 months (range 5-76). Complete remission (CR) with CT alone was achieved in 12/28 (431%) patients, CR with CT associated to radical surgery in 4/28 (14%) patients, with a total of 16/28 (57%) patients becoming disease-free. CR was achieved in 6/7 (86%) patients with minimal advanced disease and alI of them are long term disease free survivors. CR was achieved in 10/21 (47,6%) patients with bulky advanced disease and five (24%) of them are still in their first remission. PVB was an effective and well tolerated treatment for patients with minimal advanced disease but were of less eficacy (only 24% Jong term disease free survivors) in those with bulky disease. Survival curve as described by Kaplan-Meier method, showed a media, survival of 36.6 months and a four-year disease free survival of 48010 patients. Discussion about new chemotherapeutic treatments are presented.Vinte e oito pacientes portadores de tumores germinativos do testículo foram tratados com Cisplatinum, Vinblastina e Bleomicina e observados por um período mediano de 33,5 meses. Remissão completa (RC) com quimioterapia isolada foi obtida em 13/28 (43%). Outros 4 entraram em remissão completa com a associação de quimioterapia e cirurgia, perfazendo um total de 16/28 (57%) de pacientes livres de doença. Nos pacientes considerados como portadores de doença mínima encontramos 6/7 (86%) em RC, sendo que não houve nenhuma recidiva neste grupo de pacientes. Naqueles considerados como portadores de doença avançada encontramos 10/21 (47,6%) em RC sendo que apenas cinco permaneceram continuamente sem evidências de doença e um deles foi resgatado com um esquema de segunda linha. O PVB foi bem tolerado e é muito eficaz nos pacientes portadores de doença mínima. No entanto, nos pacientes com doença avançada apenas 24% obtiveram uma remissão completa prolongada e provavelmente a cura. A curva de sobrevida calculada pelo método de Kaplan-Meier revelou sobrevida mediana de 36.6 meses e sobrevida a 4 anos de 48% dos pacientes.INCA2023-08-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/323810.32635/2176-9745.RBC.1986v32n2.3238Revista Brasileira de Cancerologia; Vol. 32 No. 2 (1986): June; 81-88Revista Brasileira de Cancerologia; Vol. 32 Núm. 2 (1986): jun.; 81-88Revista Brasileira de Cancerologia; v. 32 n. 2 (1986): jun.; 81-882176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/3238/2095https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMoreira, Wagner BrantBrandão, Eduardo CarvalhoNascimento, EduardoLopes, Eugênio BaumgratzTeixeira, João Augusto M.Vieira, Maria do Carmo L. R.Alvares, Maria NunesCabral Filho, Sebastião2023-08-07T18:18:21Zoai:rbc.inca.gov.br:article/3238Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2023-08-07T18:18:21Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
title Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
spellingShingle Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
Moreira, Wagner Brant
Tumor Testicular
Quimioterapia
Testicular Tumor
Chemotherapy
title_short Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
title_full Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
title_fullStr Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
title_full_unstemmed Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
title_sort Quimioterapia com Cisplatinum, Vinblastina e Bleomicina (PVB) em Pacientes Portadores de Tumores Germinativos Avançados do Testiculo
author Moreira, Wagner Brant
author_facet Moreira, Wagner Brant
Brandão, Eduardo Carvalho
Nascimento, Eduardo
Lopes, Eugênio Baumgratz
Teixeira, João Augusto M.
Vieira, Maria do Carmo L. R.
Alvares, Maria Nunes
Cabral Filho, Sebastião
author_role author
author2 Brandão, Eduardo Carvalho
Nascimento, Eduardo
Lopes, Eugênio Baumgratz
Teixeira, João Augusto M.
Vieira, Maria do Carmo L. R.
Alvares, Maria Nunes
Cabral Filho, Sebastião
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Moreira, Wagner Brant
Brandão, Eduardo Carvalho
Nascimento, Eduardo
Lopes, Eugênio Baumgratz
Teixeira, João Augusto M.
Vieira, Maria do Carmo L. R.
Alvares, Maria Nunes
Cabral Filho, Sebastião
dc.subject.por.fl_str_mv Tumor Testicular
Quimioterapia
Testicular Tumor
Chemotherapy
topic Tumor Testicular
Quimioterapia
Testicular Tumor
Chemotherapy
description Twenty eight available patients with advanced germ cell testis cancer were treated by combination chemotherapy (CT) with Cisplatinun, Vinblastine and Bleomycin (PVB) and followed by a median period of 35.5 months (range 5-76). Complete remission (CR) with CT alone was achieved in 12/28 (431%) patients, CR with CT associated to radical surgery in 4/28 (14%) patients, with a total of 16/28 (57%) patients becoming disease-free. CR was achieved in 6/7 (86%) patients with minimal advanced disease and alI of them are long term disease free survivors. CR was achieved in 10/21 (47,6%) patients with bulky advanced disease and five (24%) of them are still in their first remission. PVB was an effective and well tolerated treatment for patients with minimal advanced disease but were of less eficacy (only 24% Jong term disease free survivors) in those with bulky disease. Survival curve as described by Kaplan-Meier method, showed a media, survival of 36.6 months and a four-year disease free survival of 48010 patients. Discussion about new chemotherapeutic treatments are presented.
publishDate 2023
dc.date.none.fl_str_mv 2023-08-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/3238
10.32635/2176-9745.RBC.1986v32n2.3238
url https://rbc.inca.gov.br/index.php/revista/article/view/3238
identifier_str_mv 10.32635/2176-9745.RBC.1986v32n2.3238
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/3238/2095
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 32 No. 2 (1986): June; 81-88
Revista Brasileira de Cancerologia; Vol. 32 Núm. 2 (1986): jun.; 81-88
Revista Brasileira de Cancerologia; v. 32 n. 2 (1986): jun.; 81-88
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042234825113600

Registros relacionados